Maple Investment Partners
Busan, Pusan-jikhalsi, South Korea
Overview
Maple Investment Partners is a venture capital firm that invests in small and medium-sized venture companies. Maple Investment Partners presents the optimal deal structure for each stage of growth of SMEs and executes investments through the formation and management of funds such as SME Startup Investment Association and Korea Venture Investment Association. In addition to venture investment, Maple Investment Partners carries out various investment activities such as Private Equity (PE) and has professional manpower responsible for such investment.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 0
Sector focus
- Business Development
- Financial Services
- Small and Medium Businesses
- Venture Capital
Investment portfolio
- Dnotitia
Participated · Series A · Apr 2026
Dnotitia develops an AI storage stack centered on Seahorse, a vector database, and VDPU, a dedicated vector data processing semiconductor. In March the company unveiled an AI Storage Strategy to integrate external knowledge, long-term memory, and working memory. Seahorse received Korea’s top-grade GS software certification in January and Seahorse Cloud was launched as a SaaS offering in March. Dnotitia describes VDPU as a purpose-built chip for accelerating vector data search and processing and is preparing it for commercialization. The company plans to use its recent Series A proceeds to improve cloud and on‑premises products, commercialize VDPU, expand globally, and hire key talent. Dnotitia is also moving forward with IPO preparations, naming Korea Investment & Securities and Shinhan Securities as joint lead managers.
- Illimis Therapeutics
Participated · Series B · Jul 2025
Illimis Therapeutics develops therapies for central nervous system and immune disorders using its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. The company's lead program, ILM01 for Alzheimer's Disease, is entering preclinical development in the second half of 2025 with an IND targeted by the end of 2027. Proceeds from the recent financing will accelerate GAIA-based Alzheimer's programs, expand target indications into various immune disorders, and broaden its pipeline toward potential blockbuster candidates. Illimis is pursuing early-stage co-development with global pharmaceutical companies and research institutions and has established collaborations including Eli Lilly's Catalyze360-ExploR&D, participation in BMS Innovation Square Challenge, and membership in JLABS Singapore. A Scientific Advisory Board that includes Dr. Greg Lemke and Dr. Morgan Sheng provides strategic guidance across R&D, candidate discovery, and clinical trial design. The company was selected for the '2025 Global Joint Research to Defeat Dementia' and secured KRW 2.2 million ($1.6 million) in funding over three years to support international Alzheimer's research efforts.
- Algocare
Participated · Series A · Mar 2024
Algocare, founded in 2019, develops an AI-based healthcare platform focused on personalized nutrition management. Its core product for companies, 'Algocare at Work,' analyzes users' health data and uses an IoT device called the 'Nutrition Engine' to dispense precisely mixed daily supplements in a 4mm micro formulation. Users also receive continuous, data-driven guidance through the Algocare mobile application. The company has won CES ‘Innovation Awards’ four years running for its technology. As of March 2024, cumulative supplement intake exceeded 480,000 times, enterprise customer retention is over 88%, quarterly corporate-customer growth is 49%, and it serves about 40 corporate clients. Algocare is expanding B2B market share, running pilot deployments with companies such as Hyundai Motor, Walkerhill Hotel & Resort, and EcoPro BM, and is preparing a consumer/home solution and broader market expansion.
Team
No current team members are available.